This ones a heck of a specualive investment but it seems that the institutions are willing to stomp up the cash to back it in the long term.

Heres the latest news from Killik stocbrokers on the company..........

MEDICAL MARKETING Joint Venture

We recently highlighted Medical Marketing (MMG) as worthy of attention. The company, in which I have a personal share holding, has this morning announced the formation of a joint venture, Genvax, to develop a novel DNA vaccine platform technology.

Human trials have been underway since 2001 in areas such as Lymphoma and Myeloma but the technology has broad applications in cancer, viral and bacterial infections (hence the term platform). The technology works on boosting the immune system by teaching it to identify hard to recognise cancer proteins as foreign and destroy them. Early results from the 25 patient trial in lymphoma are encouraging and evaluation of the result is expected by March 2005. Successful results should mean big pharmaceutical groups will start to take financial and commercial interests around that time.

This looks to be the first of a series of announcements due from Medical Marketing as it has a range of predominantly cancer trials moving into the clinical stage. (news flow could push the price higher)

The stock has made good progress in recent sessions up to the mid-80p level where the company is valued at just under 40 million. ENDS.

Please DYOR

cheers GF.

Moving higher , now up over 11%.

cheers GF.

28/01/2005 - MMI's ruthenium cancer therapy passes independently verified safety tests


Medical Marketing International Group plc (AIM:MMG), the Cambridge, UK-based pharmaceutical development company today announces that lead ruthenium compounds within its portfolio of cancer therapies show toxicity at an even safer level than tamoxifen, one of the safest cancer drugs currently available, when tested in an industry standard laboratory model.


Independent laboratory tests show ruthenium to have a low toxicity profile
Efficacy of ruthenium shown to be better than market-leading platinum drugs
Patents recently granted in biggest markets, USA and EU giving long patent protection. Other patents are pending.



MMI has already shown that the ruthenium cancer therapies within its wholly-owned subsidiary, Oncosense, appear in laboratory tests to be more powerful than the platinum-based drugs which have been some of the most successful cancer drugs for decades and which had peak sales of $5bn. Efficacy of these compounds has also been independently demonstrated in both human cancer cells and in vivo models. MMI recently announced that patents in USA and Europe, the two biggest markets have been granted, and other patents are pending.


MMI used the Dundee-based specialist, CXR Biosciences Ltd to test the most promising ruthenium compounds for potential toxicity. A summary of the CXR results is announced today.


Mark Burton, Technical Manager at MMI said: "We chose CXR because of their highly regarded expertise in screening new drugs for harmful effects. Not only did CXR deliver the results on time and on budget, they were able to show that our ruthenium cancer therapies demonstrate a low toxicity profile. These results, when added to the existing efficacy data show that ruthenium has great clinical potential."

Dr Cliff Elcombe Director at CXR and former Senior Scientist at Zeneca said: "We feel privileged to have been chosen by MMI to carry out the safety studies on what now appears to be an extremely interesting new class of cancer drugs. The safety screens that we performed indicate that this new group of cancer therapies has enormous potential."

Executive Chairman of MMI Group, David Best, commenting on these results said: "Ruthenium is only one of MMI's portfolio of excellent drug candidates, but already data show it to be potentially the most effective drug against serious cancers like lung, colon and ovarian. This new data from CXR shows ruthenium to be potentially relatively safe too. If these results are confirmed in the clinical trials, then ruthenium may improve significantly on the standard treatment for cancer patients and become a major commercial success in a cancer therapy market that was worth $42 billion in 2004 and continues to grow in double-digit figures."

Killicks are pushing this one and NLR both of which I hold...perhaps old Kav has got it right this time around since the Tech collpase of 2000..?

Buys still coming in.

cheers GF.

A few taking weekend pocket money now. Great week for this one and should move up again next week.

cheers GF.

Sad to do it but I finally ditched boring PAY to add to SEO and MMG. GF are you still following PAY? I am hoping the pundits will finally wake up to this as another potential NLR but until then my money is off elsewhere!! cheers MP

Sure am MP but not putting any more funds in.

cheers GF.

I see Mike Walters on his site as given this one another good update after the Pru went in and increased its stake.

cheers GF.

Should have some news from Oncosense by the end of the month and it should be good...Genvax news end April so we will have to wait a bit longer..

Bit of profit taking going on at the moment.

cheers GF.

Bound to happen. Bigger things to come so hold on.

MS

A VOTE OF CONFIDENCE from Mike Walters.......................

[Read more]
More Prudent
2/2/2005

The Pru has bought more Medical Marketing. Good

cheers GF.

Hope so i bought in to this a bit late..

Down 6p now, a great opportunity for those who missed out earlier to jump on board.

cheers GF.

Ive just added on the pull back, these could turn out to be derd cheap and we know that 6 or more products are going into clinical trials this year.

From results December...............

In addition to the Oncosense clinical trials, we continue to make progress with
our anti-viral business, Viratis where I am pleased to report that the European
patent was formally granted. Genvax, our DNA vaccine business, is also
progressing. Some of the DNA vaccines are already in clinical trials involving
cancer patients and other cancer vaccines are due to enter clinical trials
shortly. Overall we expect to have some six or more products in clinical trials
in 2005, with the results of some of these trials being available in the first
half of the year. Our pharmaceutical portfolio is therefore most promising

Those who have sold this morning must be stark raving mad.

cheers GF.

WOW, just look at those buys coming in and the price as come back in aswell. Come on MMG we want you in the blue before the days out.

cheers GF.

GF ,I got in late on this one and nearly sold out today, thanks for the reasurance Jb

Hi Jimmy, please remember its a very sensitive one this with a very high beta.

6 or more product annoucements the first later this month shouls assure holders and entice new buyers in.

cheers GF.

In on this one at 103p. That rally after the sell off convinced me this one's stil got a way to go.

More from Mike..Its free....

http://www.michaelwalters.com/stories/news.phtml?num=2416